Loading...

TCR2 Therapeutics

DB:2K7
Snowflake Description

Flawless balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
2K7
DB
$439M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The last earnings update was 23 days ago. More info.


Add to Portfolio Compare Print
2K7 Share Price and Events
7 Day Returns
8%
DB:2K7
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-
DB:2K7
-10.2%
DE Biotechs
-6%
DE Market
2K7 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
TCR2 Therapeutics (2K7) 8% -7.3% - - - -
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • No trading data on 2K7.
  • No trading data on 2K7.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is TCR2 Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether TCR2 Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as TCR2 Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for TCR2 Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €15.118.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for TCR2 Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are TCR2 Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:2K7 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-98.53
NasdaqGS:TCRR Share Price ** NasdaqGS (2019-04-18) in USD $18.35
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of TCR2 Therapeutics.

DB:2K7 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:TCRR Share Price ÷ EPS (both in USD)

= 18.35 ÷ -98.53

-0.19x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TCR2 Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • TCR2 Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does TCR2 Therapeutics's expected growth come at a high price?
Raw Data
DB:2K7 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.19x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-17.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for TCR2 Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on TCR2 Therapeutics's assets?
Raw Data
DB:2K7 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-117.88
NasdaqGS:TCRR Share Price * NasdaqGS (2019-04-18) in USD $18.35
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:2K7 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:TCRR Share Price ÷ Book Value per Share (both in USD)

= 18.35 ÷ -117.88

-0.16x

* Primary Listing of TCR2 Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TCR2 Therapeutics has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.

Next steps:

  1. Examine TCR2 Therapeutics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through TCR2 Therapeutics's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Biotechs industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess TCR2 Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. TCR2 Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is TCR2 Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-17.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is TCR2 Therapeutics expected to grow at an attractive rate?
  • Unable to compare TCR2 Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare TCR2 Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare TCR2 Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:2K7 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:2K7 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -17.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:2K7 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:2K7 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 54 -126 -120 3
2022-12-31 5 -123 -120 4
2021-12-31 0 -101 -103 4
2020-12-31 0 -67 -72 4
2019-12-31 0 -42 -48 4
DB:2K7 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -19 -62
2018-09-30 -17 -55
2017-12-31 -12 -15
2016-12-31 -9 -11

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • TCR2 Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if TCR2 Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:2K7 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from TCR2 Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2K7 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -3.11 -2.56 -3.92 3.00
2022-12-31 -3.51 -2.71 -4.25 4.00
2021-12-31 -3.42 -2.85 -4.48 4.00
2020-12-31 -2.84 -2.32 -3.53 4.00
2019-12-31 -1.95 -1.74 -2.08 4.00
DB:2K7 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -98.53
2018-09-30 -99.13
2017-12-31 -39.94
2016-12-31 -38.64

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if TCR2 Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess TCR2 Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
TCR2 Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has TCR2 Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare TCR2 Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • TCR2 Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare TCR2 Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare TCR2 Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
TCR2 Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from TCR2 Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:2K7 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -61.55 9.48 16.98
2018-09-30 -54.66 5.85 16.20
2017-12-31 -14.86 5.03 8.15
2016-12-31 -10.70 2.26 7.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if TCR2 Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if TCR2 Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if TCR2 Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess TCR2 Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
TCR2 Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is TCR2 Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up TCR2 Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • TCR2 Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • TCR2 Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of TCR2 Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • TCR2 Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from TCR2 Therapeutics Company Filings, last reported 3 months ago.

DB:2K7 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 123.53 0.00 123.17
2018-09-30 130.46 0.00 131.00
2017-12-31 20.78 0.00 19.81
2016-12-31 17.29 0.00 16.34
  • TCR2 Therapeutics has no debt.
  • TCR2 Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • TCR2 Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • TCR2 Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 31.7% each year.
X
Financial health checks
We assess TCR2 Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. TCR2 Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is TCR2 Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from TCR2 Therapeutics dividends.
If you bought €2,000 of TCR2 Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate TCR2 Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate TCR2 Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:2K7 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:2K7 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as TCR2 Therapeutics has not reported any payouts.
  • Unable to verify if TCR2 Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of TCR2 Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as TCR2 Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess TCR2 Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can TCR2 Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. TCR2 Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of TCR2 Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Garry Menzel
COMPENSATION $2,834,075
AGE 54
TENURE AS CEO 3.3 years
CEO Bio

Dr. Garry E. Menzel, Ph.D. serves as President, Chief Executive Officer and Director of TCR2, Inc. Dr. Menzel served as the Chief Strategy and Financial Officer of Axcella Health, Inc. Dr. Menzel served as Chief Business and Strategy Officer at Axcella Health, Inc. since October 19, 2015. Dr. Menzel served as the Chief Financial Officer of DaVita HealthCare Partners Inc. from September 30, 2013 to March 2015. Dr. Menze served as Senior Vice President of Finance at DaVita HealthCare Partners Inc. from September 16, 2013 to September 30, 2013. He served as the Chief Operating Officer and Executive Vice President of Finance at Regulus Therapeutics Inc. (Regulus Therapeutics, LLC) from January 2009 to June 21, 2013. Dr. Menzel served as the Chief Financial Officer of Regulus Therapeutics Inc. Dr. Menzel served as an Executive Vice President of Corporate Development & Finance of Regulus Therapeutics LLC from August 2008 to January 2009. Dr. Menzel served as Senior Vice President and Head of Global Biotechnology Investment Banking of Goldman Sachs, which he joined in 1994. He led the IPO and significant strategic partnerships with Astra Zeneca, GlaxoSmithKline and Sanofi. He served as Global Head of Life Sciences for Credit Suisse. Dr. Menzel served as Consultant of Bain & Company. He served as the Managing Director and Founding Member of the Healthcare Group. Dr. Menzel was employed by Credit Suisse (USA), Inc. and The Goldman Sachs Group, Inc. Dr. Menzel joined Credit Suisse in 2004 and served as its Managing Director. He served a broad range of biotechnology and pharmaceutical clients around the world, raising capital and negotiating merger agreements for some of its most significant transactions. He serves as Director Emeriti of the Institute for Systems Biology. Dr. Menzel serves as an Executive Board Member of the Epilepsy Therapy Project. He served as a Director of Endeavor Pharmaceuticals Inc., since 2001. He is Associate of the Royal College of Science. Dr. Menzel earned a B.Sc. with honors in Biochemistry from Imperial College of Science & Technology in 1985, a Ph.D. in Molecular Biology from the University of Cambridge in 1988 and an M.B.A. from the Stanford Graduate School of Business in 1994.

CEO Compensation
  • Garry's compensation has increased whilst company is loss making.
  • Garry's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the TCR2 Therapeutics management team in years:

2.4
Average Tenure
49
Average Age
  • The tenure for the TCR2 Therapeutics management team is about average.
Management Team

Garry Menzel

TITLE
President
COMPENSATION
$3M
AGE
54
TENURE
3.3 yrs

Robert Hofmeister

TITLE
Chief Scientific Officer
COMPENSATION
$822K
AGE
51
TENURE
2.5 yrs

Alfonso Cardama

TITLE
Chief Medical Officer
COMPENSATION
$925K
AGE
47
TENURE
2.3 yrs

Ian Somaiya

TITLE
Chief Financial Officer
AGE
45
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the TCR2 Therapeutics board of directors in years:

3.4
Average Tenure
59
Average Age
  • The tenure for the TCR2 Therapeutics board of directors is about average.
Board of Directors

Ansbert Gadicke

TITLE
Chairman of the Board of Directors
AGE
60

Garry Menzel

TITLE
President
COMPENSATION
$3M
AGE
54
TENURE
3.3 yrs

Morana Jovan-Embiricos

TITLE
Director
COMPENSATION
$127K
AGE
51
TENURE
3.5 yrs

Neil Gibson

TITLE
Director
COMPENSATION
$55K
AGE
62
TENURE
1.2 yrs

Andrew Allen

TITLE
Director
COMPENSATION
$54K
AGE
51
TENURE
0.3 yrs

Patrick Baeuerle

TITLE
Director
COMPENSATION
$76K
AGE
60
TENURE
3.9 yrs

Mitch Finer

TITLE
Director
COMPENSATION
$76K
AGE
59
TENURE
3.5 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by TCR2 Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
21. Feb 19 Buy China Molybdenum Co., Ltd. Company 19. Feb 19 19. Feb 19 200,000 €13.24 €2,647,500
21. Feb 19 Buy Morana Jovan-Embiricos Individual 19. Feb 19 19. Feb 19 366,667 €13.24 €4,853,754
21. Feb 19 Buy MPM Capital Company 19. Feb 19 19. Feb 19 1,373,333 €13.24 €18,179,496
21. Feb 19 Buy MPM Capital Company 19. Feb 19 19. Feb 19 666,667 €13.24 €8,825,004
21. Feb 19 Buy F2-Tpo Investments, Llc Company 19. Feb 19 19. Feb 19 133,333 €13.24 €1,764,996
21. Feb 19 Buy F2 Mg Limited Company 19. Feb 19 19. Feb 19 166,667 €13.24 €2,206,254
X
Management checks
We assess TCR2 Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. TCR2 Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Details
Name: TCR2 Therapeutics Inc.
2K7
Exchange: DB
Founded: 2015
$390,623,055
23,939,901
Website: http://www.tcr2.com
Address: TCR2 Therapeutics Inc.
100 Binney Street,
Suite 710,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS TCRR Common Stock Nasdaq Global Select US USD 14. Feb 2019
DB 2K7 Common Stock Deutsche Boerse AG DE EUR 14. Feb 2019
MUN 2K7 Common Stock Boerse Muenchen DE EUR 14. Feb 2019
Number of employees
Current staff
Staff numbers
48
TCR2 Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 22:16
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.